Preserved in Portico This version is not peer-reviewed
Status and Contribution of CRISPR/Cas9 Based Gene-Editing System in the Development of a Low-Immunogenic Wheat Variety
: Received: 19 February 2020 / Approved: 21 February 2020 / Online: 21 February 2020 (02:14:36 CET)
: Received: 28 September 2021 / Approved: 29 September 2021 / Online: 29 September 2021 (15:39:12 CEST)
A peer-reviewed article of this Preprint also exists.
Journal reference: Foods 2021, 10
Gluten, a wheat protein, contains epitopes that trigger celiac disease (CD). So far, there is no treatment available for CD other than following a life-long, strict gluten-free diet (GFD). A very low-gluten or gluten-free wheat could provide an alternative treatment to CD. Till date, conventional plant breeding methods are not sufficient to produce celiac-safe wheat. Clustered Regularly Interspaced Short Palindromic Repeats-associated protein 9 (CRISPR/Cas9) is a versatile gene-editing system may efficiently edit the immunogenic gluten protein thereby producing a celiac-safe wheat variety. However, CRISPR/Cas9-mediated genome editing system has not been widely investigated to edit the wheat genome. Published literature available on various scientific platforms, that applied the CRISPR/Cas9 system to edit the wheat genome were explored. Only original research articles were included. Review articles, protocols, scientific presentations, and Ph.D. thesis were excluded. CRISPR/Cas9 is a highly specific gene-editing technology that can be used to efficiently edit the complex hexaploid wheat genome. It targets a specific wheat genome locus, delete an immunogenic gene and replace it with a preferred gene. CRISPR/Cas9 technology could be a breakthrough in providing an alternative treatment for CD. However, further studies are required to efficiently apply this gene-editing technology to develop a celiac-safe wheat variety.
CRISPR/Cas9; celiac disease; wheat; sgRNA; gluten; low-immunogenic wheat
MEDICINE & PHARMACOLOGY, Gastroenterology
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.